Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2015-02-17 Major Shareholding Noti…
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G AMENDMENT FILING
Major Shareholding Notification
2015-02-17 English
SC13GA LANDEC DEC14
Major Shareholding Notification
2015-02-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports a material impairment charge related to the company's investment in Aesthetic Sciences Corporation. The document includes details about the impairment, the background of the investment, and the expected financial impact. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not an announcement of a report publication but a standalone regulatory filing reporting a material event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-02-12 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated February 5, 2015. The key content is an announcement regarding the delay in retirement of the company's President, CEO, and Chairman of the Board, Gary T. Steele, and his agreement to remain on the Board after retirement. This is a clear announcement of a change in senior management. There are no financial statements or detailed financial data included, and the document is relatively short (2328 characters). Therefore, it is not an annual report, earnings release, or other financial report. The appropriate classification is Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2015-02-05 English
SCHEDULE 13G/A
Major Shareholding Notification
2015-02-05 English
Major Shareholding Notification 2015
Major Shareholding Notification
2015-01-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.